IVD's and LDT's - What's the difference?

Wednesday, April 08, 2009

One difference is the regulatory path to market and the regulatory body authorized to regulate them. Under the current U.S. regulatory framework molecular diagnostic tests (including genetic tests) have two compliant paths to market: the IVD path or the LDT path.

In vitro diagnostic devices (IVD) are developed and manufactured by device manufacturers under the Quality System Regulation (QSR) and unless exempt require premarket approval or 510(k) notification prior to sale and distribution. FDA has the authority to regulate devices that are distributed as IVD's as well as those that are distributed for "Investigational Use Only" (IUO)  and for "Research Use Only" (RUO).

Laboratory Developed Tests (LDT's), also referred to as Homebrews, are diagnostic tests that are developed and manufactured by CLIA certified laboratories under their Quality Management System.  These tests are developed by the lab for use only in that laboratory.  CLIA laboratories develop the performance characteristis, perform the analytical validation for their LDT's and obtain licenses to offer them as diagnostic services.  The Centers for Medicare & Medicaid Services (CMS) has the authority to regulate clinical laboratories and  LDT’s under Clinical Laboratory Improvement Act of 1988 (CLIA ’88). CLIA ’88 established requirements that laboratories need to meet to perform various types of testing. These include certification and inspection.   

Stay tuned for more on IVD's and LDT's.


Other Blog Authors

Mya Thomae
Dylan Reinhardt
Dave Kern
Steve Gutman

Recent Blog Posts

The Staple That Changed an Industry LDT regulation and the perils of challenging Eminem to a rap battle
FDA Releases the Kraken Whichever way this breaks, it's long past time to have this conversation in a meaningful way
Illumina Acquires Myraqa Acquisition Strengthens Illumina’s Clinical Readiness
The Spirit of GLP A Best Practice for IVDs
Process Performance Qualification (PPQ) Lots So, how many lots are required?
The Case for Risk-based Monitoring Better the devil you know...
Form Follows Function OIR Reorganizes to Meet the Advancing Wave of Molecular Diagnostics
CDRH Unveils New PMA Guidance Documents Attention shoppers, it's two-for-one day!